Bermuda cited in New York Times tax avoidance report

Bermuda’s new 15% corporate income tax under OECD Pillar 2 is forcing multinational companies to rework tax structures, with Apollo disclosing a $1.7 billion accounting charge after tax assets tied to future Bermuda liabilities were no longer expected to be realized. Pepsi said Bermuda-linked structures helped cut its tax bill by $691 million last year, while AbbVie disclosed a $104 million Bermuda tax-rate differential and $286 million of related valuation allowances. The article is largely about tax reform, disclosure changes, and scrutiny of offshore structures rather than a single company-specific earnings event.

Analysis

This is less a pure reputational story than a regime-change story for cross-border tax engineering. The key second-order effect is that Pillar 2 is forcing multinationals to move from jurisdictional arbitrage to balance-sheet and entity-structure cleanup, which creates a near-term cash tax headwind and a multi-quarter accounting overhang as deferred tax assets get remeasured. The immediate losers are companies with large legacy Bermuda/IP or reinsurance structures, because the market will now focus on the gap between reported effective tax rates and sustainable cash tax rates.

The biggest practical risk is not the new statutory rate itself but the transition friction: valuation allowance charges, audit risk, and the chance that old structures become uneconomic faster than management can reposition capital. For insurers/reinsurers and pharma names, that can mean a muted but persistent drag on EPS revisions over the next 2-4 quarters, plus periodic one-off charges whenever tax assets are written down. For firms with aggressive intercompany financing, the market should expect higher scrutiny of deductible interest flows and more jurisdictional data disclosures that invite activist, legal, and congressional attention.

The market may be underpricing how asymmetric this is across sectors. Companies with simpler supply chains and less IP mobility should see little fundamental impact but could still benefit from a relative rerating if peers absorb tax friction and guidance uncertainty. Conversely, firms that used Bermuda as a tax reservoir now face a harder optimization problem: any attempt to re-route profits into alternative low-tax jurisdictions increases transfer-pricing and audit risk, so the benefit likely decays rather than migrates cleanly. The most likely reversal catalyst is not a policy rollback but a settlement cycle that clarifies what is sustainable, which could take 6-12 months and leave a trail of negative revisions before stabilization.

Key Decisions for Investors

• Short PEP on a 1-3 month horizon vs. a consumer staples basket: the tax benefit story is increasingly vulnerable to incremental disclosures and audit noise; use tight risk controls because the core business is defensive.
• Underweight ABBV relative to large-cap pharma over the next 2 quarters: the combination of foreign tax-rate sensitivity, valuation allowance risk, and Pillar 2 uncertainty argues for a relative short until guidance normalizes.
• Short a basket of companies with legacy Bermuda-heavy structures and intercompany financing exposure; prefer names where the market has already priced in growth but not a higher sustainable cash tax rate.
• Buy optionality on NYT near-term around the next disclosure cycle: the incremental value is in continued jurisdictional transparency and follow-on reporting, not the initial headline.
• Avoid initiating fresh longs in APOS until the tax charge cadence is clearer; if already long, hedge with sector peers less exposed to cross-border tax asset remeasurement.